Plavix patent fight could hurt Lilly's blood-thinning drug

08/16/2006 | Fort Worth Star-Telegram (Texas)

Analysts say the patent fight pitting Bristol-Myers Squibb and Sanofi-Aventis against generics maker Apotex could affect Eli Lilly's pipeline drug prasugrel if Apotex is allowed to continue selling the generic form of Plavix. Analysts say that if research fails to show there is significant difference between the new Lilly product and the generic Plavix, sales of prasugrel could be hit. A Lilly executive says the company is testing Plavix and prasugrel head-to-head because it anticipates competition against a generic.

View Full Article in:

Fort Worth Star-Telegram (Texas)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY
Director of Payor/Provider Contracting
U.S. Medical Management
Tryo, MI